The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions

Kraehenmann and colleagues situate this work within a resurgence of clinical research on psychedelic-assisted psychotherapy, noting that psilocybin has shown safety and potential efficacy for alcohol dependence in an open-label pilot and that a larger FDA-approved Phase II trial was underway. They describe the typical treatment structure used in these studies: a 12-week psychotherapy programme with two psilocybin medication sessions (weeks 4 and 8), therapists working as a co-therapist dyad, and debriefing sessions held the day after medication sessions to assess mental status and to allow patients to describe and reflect on their experiences. The paper aims to characterise how participants themselves talk about change-related phenomena during these immediate post-medication debriefing sessions. Because detailed descriptions of what actually occurs in clinical psychedelic-assisted psychotherapy are scarce, the investigators analysed transcripts of debriefing sessions from their open-label pilot to illustrate phenomena—such as mysticomimetic experiences, ego-dissolution, motivation, commitment to change, dysphoria, and stigma—that may relate to changes in drinking behaviour and to therapeutic mechanisms more broadly.

This analysis used transcripts from an open-label pilot study (NCT01534494) of psilocybin-assisted treatment for alcohol dependence in which ten participants meeting DSM-IV-TR criteria were enrolled. The clinical protocol comprised 14 psychotherapy sessions over 12 weeks, including two psilocybin medication sessions (week 4 and week 8) and corresponding debriefing sessions conducted the following day. Psilocybin dosing was oral, initially 0.3 mg/kg for the first session and 0.4 mg/kg for the second session unless clinical reasons or participant choice dictated retention of the lower dose. Seven participants completed both medication/debriefing pairs and three completed only one, yielding 17 debriefing session transcripts for analysis. Participants were screened to exclude significant medical or psychiatric comorbidity, family history of schizophrenia or bipolar disorder, dependence on stimulants or opioids, and substantial prior hallucinogen exposure. The study collected several quantitative measures of acute subjective effects of psilocybin: the 43-item Mystical Experience Questionnaire (MEQ) to index ‘‘mysticomimetic’’ phenomena, the Hallucinogen Rating Scale (HRS) intensity subscale, and the Altered States of Consciousness (ASC) scale (the blissful state subscale is reported). MEQ scores from each participant’s first session were used, along with clinical judgment, to decide whether to offer a dose increase for the second session. For the qualitative component, the investigators performed a directed content analysis using Atlas.ti. Initial coding categories were theory-driven and reflected phenomena of interest in the psychedelic and addiction literatures: mysticomimetic experiences (subdomains of the MEQ), ego-dissolution, relationship to alcohol, motivation, commitment to change, dysphoric experiences, stigma, interpersonal interactions, music, therapist/participant relationship, and difficult session content. The first author developed and applied initial codes to all transcripts, then presented categories and coded excerpts for collaborative review by co-authors (including those who had conducted the sessions). A secondary keyword search was used to capture missed material. After coding, seven categories emerged with substantial material; the authors describe each category and the process for selecting exemplar participant utterances. The extracted text does not clearly report whether an independent reliability check (e.g. kappa) was performed for coding.

Seventeen debriefing sessions totalling 899 minutes were analysed: two sessions each from seven participants and one session each from three participants. The fourth author conducted all debriefings, usually with a co-therapist present. Quantitative acute-effect data reported in the extracted text indicate mean HRS intensity in first sessions (dose 0.3 mg/kg, N = 10) was 2.43 (SD 1.03) and in second sessions (dose 0.4 mg/kg, N = 6) was 2.0 (SD 1.14). One participant (Adam) did not increase dose because his first-session intensity was >1 SD above the mean and he uniquely scored >0.6 on all MEQ subscales for his first session. Coding and thematic analysis identified multiple recurrent phenomena. Mysticomimetic experiences (internal/external unity, noetic quality, sacredness, transcendence of time/space, and ineffability) were present in debriefings, but were detected by the MEQ above the a priori >0.6 criterion in only three of the 17 sessions. Excerpts from high-MEQ sessions illustrate classical features: reports of oneness, feelings of direct connection with God or a ‘‘bigger ultimate place,’’ and statements that the experience was difficult to capture in words (ineffability). Ego-dissolution was explicitly mentioned across transcripts; the authors report 13 observed instances, 10 of which came from transcripts corresponding to high MEQ scores, suggesting an association between mysticomimetic intensity and descriptions of loss or alteration of self-boundaries. Participant accounts ranged from partial loosening of selfhood with comfort in retaining identity to moments of ‘‘being gone’’ and reconstituting a self seen as different (for example, references to an ‘‘old Adam’’ and a ‘‘new Adam without alcohol’’). Participants routinely discussed their relationship to alcohol during debriefings, as therapists explicitly asked about this. The analysis captured examples of motivation for change and commitment language consistent with the Motivational Enhancement Therapy (MET) approach used in the study. Several participants expressed concrete intentions and readiness to change. Dysphoric or challenging experiences during psilocybin sessions were also reported; these were commonly framed by participants as meaningful and sometimes growthful. Illustrative quotations describe fear, crying, nightmares, and intense emotional material often resolved or contextualised during debriefings. The authors note an informative discordance for one participant (Heather), who exhibited very low subjective-effect scores on MEQ/HRS/ASC across both sessions yet achieved a 100% reduction in heavy drinking days, raising possibilities about non-subjective mechanisms, efficacy of MET alone, or measurement anomalies. The extracted text does not provide detailed counts or percentages for how frequently each theme occurred across all transcripts beyond the instances noted for ego-dissolution and the count of high-MEQ sessions.

Kraehenmann and colleagues interpret their findings as evidence that multiple phenomena—rather than a single factor—may contribute to clinical change in psilocybin-assisted treatment for alcohol dependence. They emphasise that mysticomimetic experiences have a longstanding presence in psychedelic research and accounted for some prominent excerpts in the debriefings, but these experiences were not universal across sessions and were measurable by the MEQ in only a minority of debriefings. The authors suggest several reasons for this variability: participants may have discussed material at the end of the psilocybin session itself, memory of the experience may have shifted between the MEQ and the debriefing, doses may have been insufficient to elicit strong mysticomimetic experiences in many participants, or the phenomena simply were not as salient to some participants. The discussion highlights other relatively under-explored but potentially important themes such as stigma, and notes that Motivational Enhancement Therapy can be integrated with psychedelic preparation and integration by a co-therapist dyad to elicit change- and commitment-related talk. The authors argue that analysing actual clinical debriefing sessions offers a distinct window into what occurs in treatment compared with post hoc qualitative interviews, since sessions capture spontaneous therapeutic discourse; nevertheless, they acknowledge that the two approaches are complementary and that interviews can probe constructs not raised spontaneously in therapy. Several limitations are acknowledged. The dataset comprised only 17 debriefings from a small, open-label pilot and included considerable variability in session length, format (some phone sessions), and therapist presence; the analysis did not stratify or compare by these factors. Transcriptions were produced by four graduate assistants and may have varied in accuracy. Coding categories were inductively selected by consensus among authors rather than by pre-specified standard criteria, and the study did not employ formal recall-enhancing tasks (e.g. guided imagery) in debriefings. The authors also note concerns about changes in recall over time, citing prior work showing that participants report somewhat different phenomenology the day after an acute psychedelic session. Finally, they flag the Heather case as an example where behavioural change occurred despite limited reported subjective effects, noting that future, larger studies are needed to clarify mechanisms. The authors indicate ongoing follow-up work: two team members are initiating qualitative interviews within the ongoing randomised controlled trial to complement the present session-based analysis and address some of the limitations identified.